{"id":"NCT02185014","sponsor":"AbbVie","briefTitle":"Open Label Study to Evaluate Long Term Efficacy, Safety and Tolerability of Repeated Dosing in Subjects With Crohn's Disease and Who Participated and Successfully Completed M14-115","officialTitle":"A Multicenter, Open-Label Study to Evaluate the Long Term Efficacy, Safety, and Tolerability of Repeated Administration of Adalimumab in Subjects With Crohn's Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-08-12","primaryCompletion":"2017-11-03","completion":"2017-11-03","firstPosted":"2014-07-09","resultsPosted":"2018-11-14","lastUpdate":"2018-11-14"},"enrollment":252,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Crohn's Disease"],"interventions":[{"type":"DRUG","name":"Adalimumab","otherNames":["Humira","ABT-D2E7"]}],"arms":[{"label":"Adalimumab","type":"OTHER"}],"summary":"The purpose of this study is to evaluate the long term efficacy, safety, and tolerability of repeated administration of adalimumab in participants with Crohn's disease.","primaryOutcome":{"measure":"Percentage of Participants With Endoscopic Improvement at Week 40 in Participants With Endoscopic Improvement at Week 0","timeFrame":"Week 40","effectByArm":[{"arm":"Adalimumab","deltaMin":31.6,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":3},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":["http://rxabbvie.com/"]},"adverseEventsSummary":{"seriousAny":{"events":27,"n":252},"commonTop":["CROHN'S DISEASE","ARTHRALGIA","NAUSEA","UPPER RESPIRATORY TRACT INFECTION"]}}